CSTL (Castle Biosciences Inc) Tingkat bathi miturut bathi reged

Gross margin after deducting cost of goods sold reflects the dynamics of Castle Biosciences (CSTL), which is developing oncology diagnostics through clinic partnerships and the acquisition of AI services. An increasing number of dermatologists and insurance payouts are expanding the molecular testing market. The current metric is 74.10, however, geopolitical conflicts and reagent supply chain disruptions create serious risks for conducting global research.
Rincian analitis lan laporan data perusahaan Castle Biosciences (CSTL)

The high profitability of Castle Biosciences (CSTL) innovative tests creates powerful operating leverage, allowing the company to scale net income as unit costs decrease. By analyzing gross margin, an investor assesses the portion of revenue remaining after deducting direct production costs, which determines the fundamental efficiency of the business model and serves as the basis for calculating the company's fair value.